Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010121973 - BLOCKERS OF NMDA RECEPTOR FOR THE TREATMENT OF SICKLE CELL ANEMIA

Publication Number WO/2010/121973
Publication Date 28.10.2010
International Application No. PCT/EP2010/055077
International Filing Date 18.04.2010
IPC
A61K 31/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/13 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
A61K 31/4468 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4468having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61P 7/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
A61P 7/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
06Antianaemics
CPC
A61K 31/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
A61K 31/4468
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4468having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
A61P 7/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
A61P 7/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
06Antianaemics
Applicants
  • UNIVERSITÄT ZÜRICH [CH]/[CH] (AllExceptUS)
  • BOGDANOVA, Anna, Yulienva [RU]/[CH] (UsOnly)
  • GASSMANN, Max [CH]/[CH] (UsOnly)
  • GOEDE, Jeroen [CH]/[CH] (UsOnly)
Inventors
  • BOGDANOVA, Anna, Yulienva
  • GASSMANN, Max
  • GOEDE, Jeroen
Agents
  • Schmauder & Partner AG
Priority Data
09005683.923.04.2009EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BLOCKERS OF NMDA RECEPTOR FOR THE TREATMENT OF SICKLE CELL ANEMIA
(FR) BLOQUEURS DE RÉCEPTEUR NMDA POUR LE TRAITEMENT D'UNE DRÉPANOCYTOSE
Abstract
(EN)
Sickle cell anemia is a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions, and a prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) blocker is used for the treatment of sickle cell anemia and for manufacture of a medicament for the treatment of sickle cell anemia. Moreover, a method for screening for a compound effective in the treatment of sickle cell anemia comprises contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.
(FR)
La drépanocytose est une maladie génétique caractérisée par des globules rouges présentant une forme anormale, rigide, en faucille. Des complications aigues de la drépanocytose sont traitées symptomatiquement par des analgésiques et des transfusions, et un traitement prophylactique d'une crise de drépanocytose consiste en une application à long terme d'hydroxyurée. Selon la présente invention, un bloqueur de récepteur N-méthyl D-aspartate (NMDAR) est utilisé pour le traitement de la drépanocytose et pour la fabrication de médicaments pour le traitement de la drépanocytose. De plus, un procédé pour cribler un composé efficace dans le traitement de la drépanocytose comprend la mise en contact d'un composé candidat avec le NMDAR et la sélection dudit composé candidat considéré comme efficace si il est constaté qu'il réduit sélectivement l'activité du NMDAR.
Latest bibliographic data on file with the International Bureau